The Fly

Neximmune downgraded to Market Perform from Outperform at Raymond James

Raymond James analyst Timur Ivannikov downgraded Neximmune to Market Perform from Outperform without a price target. The analyst cites the company’s strategic program re-alignment for the downgrade and says he needs to see additional data from the AIM INJ platform in order to get more constructive on the shares. NexImmune is pausing enrollment in adoptive cell therapy studies and seeking external partnerships for NEXI-001 and NEXI-003, Ivannikov tells investors in a research note.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on NEXI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More